Baidu
map

Blood:全基因组关联分析提示免疫异常可增加霍奇金淋巴瘤的易感性

2018-09-09 MedSci MedSci原创

中心点:6p21.31、6q23.3、11q23.1、16p11.2和20q13.12上发生突变可影响HL的风险。在HL的发病机制中,遗传易感性涉及中发中心功能障碍、T细胞功能紊乱和NF-κB激活。摘要:为进一步加深我们对霍奇金淋巴瘤(HL)的遗传易感性的认识,Amit Sud等人对7个全基因组关联研究()包含5325例HL和22423例对照)进行Meta分析。研究人员在6p21.31(rs649

中心点:

6p21.31、6q23.3、11q23.1、16p11.2和20q13.12上发生突变可影响HL的风险。

在HL的发病机制中,遗传易感性涉及中发中心功能障碍、T细胞功能紊乱和NF-κB激活。

摘要:

为进一步加深我们对霍奇金淋巴瘤(HL)的遗传易感性的认识,Amit Sud等人对7个全基因组关联研究()包含5325例HL和22423例对照)进行Meta分析。

研究人员在6p21.31(rs649775,p=2.11×10-10)、6q23.3(rs1002658,p=2.97×10-8),11q23.1(rs7111520,p=1.44×10-11),16p11.2(rs6565176,p=4.00×10-8)和20q13.12(rs2425752,p=2.01×10-8)上发现了5个新的HL风险位点。

在5个新风险位点和13个已知风险位点的基因表达、组蛋白修饰和原位启动子捕获Hi-C数据集成分析提示生发中心反应功能障碍、T细胞分化和功能紊乱以及NF-κB组成性激活均是易感性的机制。

本研究进一步揭示了霍奇金淋巴瘤的遗传易感性和生物学特征。

原始出处:

Amit Sud, et al. Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma. Blood  2018  :blood-2018-06-855296;  doi: https://doi.org/10.1182/blood-2018-06-855296

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=806506, encodeId=4c2680650606, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Thu Aug 06 12:34:29 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460551, encodeId=75a81460551a9, content=<a href='/topic/show?id=36a7596628a' target=_blank style='color:#2F92EE;'>#易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59662, encryptionId=36a7596628a, topicName=易感性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6af6344165, createdName=FukaiBao, createdTime=Tue Sep 11 06:52:00 CST 2018, time=2018-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538314, encodeId=fcc615383148c, content=<a href='/topic/show?id=c83d2939eb2' target=_blank style='color:#2F92EE;'>#全基因组关联分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29397, encryptionId=c83d2939eb2, topicName=全基因组关联分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f43812955607, createdName=ailian1206, createdTime=Tue Sep 11 06:52:00 CST 2018, time=2018-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546497, encodeId=f09d154649e55, content=<a href='/topic/show?id=81eb2939373' target=_blank style='color:#2F92EE;'>#全基因组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29393, encryptionId=81eb2939373, topicName=全基因组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc2113925052, createdName=ms1692810954239974, createdTime=Tue Sep 11 06:52:00 CST 2018, time=2018-09-11, status=1, ipAttribution=)]
    2020-08-06 ms3000000449926787

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=806506, encodeId=4c2680650606, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Thu Aug 06 12:34:29 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460551, encodeId=75a81460551a9, content=<a href='/topic/show?id=36a7596628a' target=_blank style='color:#2F92EE;'>#易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59662, encryptionId=36a7596628a, topicName=易感性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6af6344165, createdName=FukaiBao, createdTime=Tue Sep 11 06:52:00 CST 2018, time=2018-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538314, encodeId=fcc615383148c, content=<a href='/topic/show?id=c83d2939eb2' target=_blank style='color:#2F92EE;'>#全基因组关联分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29397, encryptionId=c83d2939eb2, topicName=全基因组关联分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f43812955607, createdName=ailian1206, createdTime=Tue Sep 11 06:52:00 CST 2018, time=2018-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546497, encodeId=f09d154649e55, content=<a href='/topic/show?id=81eb2939373' target=_blank style='color:#2F92EE;'>#全基因组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29393, encryptionId=81eb2939373, topicName=全基因组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc2113925052, createdName=ms1692810954239974, createdTime=Tue Sep 11 06:52:00 CST 2018, time=2018-09-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=806506, encodeId=4c2680650606, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Thu Aug 06 12:34:29 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460551, encodeId=75a81460551a9, content=<a href='/topic/show?id=36a7596628a' target=_blank style='color:#2F92EE;'>#易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59662, encryptionId=36a7596628a, topicName=易感性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6af6344165, createdName=FukaiBao, createdTime=Tue Sep 11 06:52:00 CST 2018, time=2018-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538314, encodeId=fcc615383148c, content=<a href='/topic/show?id=c83d2939eb2' target=_blank style='color:#2F92EE;'>#全基因组关联分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29397, encryptionId=c83d2939eb2, topicName=全基因组关联分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f43812955607, createdName=ailian1206, createdTime=Tue Sep 11 06:52:00 CST 2018, time=2018-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546497, encodeId=f09d154649e55, content=<a href='/topic/show?id=81eb2939373' target=_blank style='color:#2F92EE;'>#全基因组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29393, encryptionId=81eb2939373, topicName=全基因组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc2113925052, createdName=ms1692810954239974, createdTime=Tue Sep 11 06:52:00 CST 2018, time=2018-09-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=806506, encodeId=4c2680650606, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Thu Aug 06 12:34:29 CST 2020, time=2020-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460551, encodeId=75a81460551a9, content=<a href='/topic/show?id=36a7596628a' target=_blank style='color:#2F92EE;'>#易感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59662, encryptionId=36a7596628a, topicName=易感性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6af6344165, createdName=FukaiBao, createdTime=Tue Sep 11 06:52:00 CST 2018, time=2018-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1538314, encodeId=fcc615383148c, content=<a href='/topic/show?id=c83d2939eb2' target=_blank style='color:#2F92EE;'>#全基因组关联分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29397, encryptionId=c83d2939eb2, topicName=全基因组关联分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f43812955607, createdName=ailian1206, createdTime=Tue Sep 11 06:52:00 CST 2018, time=2018-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546497, encodeId=f09d154649e55, content=<a href='/topic/show?id=81eb2939373' target=_blank style='color:#2F92EE;'>#全基因组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29393, encryptionId=81eb2939373, topicName=全基因组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc2113925052, createdName=ms1692810954239974, createdTime=Tue Sep 11 06:52:00 CST 2018, time=2018-09-11, status=1, ipAttribution=)]

相关资讯

Blood:非病毒RNA嵌合抗原受体修饰的T细胞用于霍奇金淋巴瘤患者的疗效和安全性

中心点:用mRNA转染自体T细胞制备抗CD19的嵌合抗原受体T细胞(CART19)是可行的。用非病毒RNA CART19靶向cHL患者的CD19+B细胞疗法,耐受性良好,并可获得一过性缓解。摘要:在多种情况下对嵌合抗原受体(CAR)修饰的T细胞进行研究,包括经典霍奇金淋巴瘤(cHL)。cHL独特的生物学特征,在免疫抑制肿瘤微环境(TME)中罕见霍奇金和RS(HRS)细胞,这可能会使直接靶向在HRS

Blood:霍奇金淋巴瘤肿瘤微环境中,CD4+效应T细胞耗竭、调节T细胞富集

中心点:新确诊的原发性cHLs伴随CD4+Th1极化调节T细胞和分化的效应T细胞增多。原发性cHLs表现出两种主要的免疫抑制互补——PD-1+Th1效应细胞耗竭和PD-1-Th1调节T细胞活化。摘要:经典型霍奇金淋巴瘤(cHL)患者抗肿瘤免疫反应失效。霍奇金RS(HRS)细胞有多种逃脱免疫细胞的机制,包括9p24.1/CD274(PD-L1)/PDCD1LG2(PD-L2)遗传变异、PD-1配体过

Blood:根据治疗间期PET/CT扫描结果,予以早期霍奇金淋巴瘤患者风险适应性的治疗

中心点:间期PET扫描阴性的小肿块的I/II期霍奇金淋巴瘤患者,进行4个疗程的ABVD治疗,无放疗,3年无进展存活率可达91%。摘要:新确诊的小肿块的I/II期霍奇金淋巴瘤(HL)患者,进行1-3个疗程的阿霉素、博来霉素、长春花碱和达卡巴嗪(ABVD)治疗后,行PET/CT检查阴性,提示复发风险低。David J. Straus等人开展一2期临床试验,探1日,究早期患者人群是否可以在PET/CT阴

Blood:晚期霍奇金淋巴瘤PET-2检查的阳性阈值

HD18研究,针对新确诊的晚期霍奇金淋巴瘤患者,在两个疗程的eBEACOPP(博来霉素、阿霉素、环磷酰胺、长春新碱、甲基苄肼和强的松[递增剂量])治疗后,进行正电子发射断层扫描(PET-2)检查,以指导进一步的治疗。Carsten Kobe等研究人员在eBEACOPP的背景下,根据Deauville评分(DS)分析PET-2结果对参与HD试验治疗的患者的影响。根据DS,将残余组织可视化,与参考区域

Haematologica:鲁索利替尼治疗晚期复发/难治性霍奇金淋巴瘤效果如何?

2018年5月,发表于《Haematologica》上的一项2期研究,考察了口服JAK1/JAK2抑制剂鲁索利替尼治疗晚期复发/难治性霍奇金淋巴瘤(HL)的效果。

2018 ESMO临床实践指南:霍奇金淋巴瘤的诊断,治疗和随访

2018年5月,欧洲肿瘤内科学会(ESMO)发布了霍奇金淋巴瘤的诊断,治疗和随访指南,文章主要内容涉及霍奇金淋巴瘤的发病率和流行病学,诊断,疾病分期和风险评估,治疗,治疗反应评估以及随访和并发症监测等。

Baidu
map
Baidu
map
Baidu
map